Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial).

J Am Heart Assoc · 2018 · PMC5866323 · PMID 29502105

Europe PMC DOI

hedged sentences

0.1000

closest p · 2.0× alpha

0.2700

boldest claim

The sentences

a nonsignificant trendP =0.1so close (0.05 < p ≤ 0.1)

We also found a nonsignificant trend toward increased risk of in‐hospital repeated revascularization in the aprotinin group (7 [1.3%] versus 2 [0.4%]; OR, 3.53; 95% CI, 0.73–17.1; P =0.1).

also in 5,406 other papers

did not reach statistical significanceP =0.27not close (p > 0.1)

Aprotinin was also associated with an increased risk of intra‐aortic balloon pump insertion (37 [6.9%] versus 17 [3.2%]; OR, 2.26; 95% CI, 1.26–4.07; P =0.006) and AKI (102 [19.0%] versus 76 [14.2%]; OR, 1.42; 95% CI, 1.03–1.97; P =0.03), although the increased risk of renal replacement therapy in the aprotinin group did not reach statistical significance (25 [4.7%] versus 18 [3.4%]; OR, 1.41; 95% CI, 0.75–2.61; P =0.27).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.